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Abstract
Background: Bone morphogenetic proteins (BMPs) and their receptors, such as bone morphogenetic protein receptor
(BMPR) II, have been implicated in a wide variety of disorders including pulmonary arterial hypertension (PAH). Similarly,
endothelin-1 (ET-1), a mitogen and vasoconstrictor, is upregulated in PAH and endothelin receptor antagonists are used in
its treatment. We sought to determine whether there is crosstalk between BMP signalling and the ET-1 axis in human
pulmonary artery endothelial cells (HPAECs), possible mechanisms involved in such crosstalk and functional consequences
thereof.
Methodology/Principal Finding: Using western blot, real time RT-PCR, ELISA and small RNA interference methods we
provide evidence that in HPAECs BMP-9, but not BMP-2, -4 and -6 significantly stimulated ET-1 release under physiological
concentrations. This release is mediated by both Smad1 and p38 MAPK and is independent of the canonical Smad4
pathway. Moreover, knocking down the ALK1 receptor or BMPR II attenuates BMP-9 stimulated ET-1 release, whilst causing a
significant increase in prepro ET-1 mRNA transcription and mature peptide release. Finally, BMP-9 induced ET-1 release is
involved in both inhibition of endothelial cell migration and promotion of tubule formation.
Conclusions/Significance: Although our data does not support an important role for BMP-9 as a source of increased
endothelial ET-1 production seen in human PAH, BMP-9 stimulated ET-1 production is likely to be important in angiogenesis
and vascular stability. However, increased ET-1 production by endothelial cells as a consequence of BMPR II dysfunction may
be clinically relevant in the pathogenesis of PAH.
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Introduction
Bone morphogenetic proteins (BMPs) are the largest subgroup
of signalling molecules in the transforming growth factor (TGF)-b
superfamily. Although originally described as osteogenic factors,
BMPs play crucial roles during embryonic development and
determine many different aspects of cell fate such as apoptosis,
proliferation, differentiation, migration, as well as angiogenesis [1].
BMPs bind to a complex of serine/threonine type I and type II
bone morphogenetic protein receptors (BMPRs) on cell mem-
branes. The type I receptor (ALK1-3 or ALK6) is activated by the
type II receptor with consequent phosphorylation of downstream
Smads (mothers against decapentaplegic homolog proteins).
Ligands for BMPRs classically signal through receptor-mediated
Smads (R-Smads) 1, 5 and 8, whereas TGF-b typically signals
through Smad2 and 3, via the ALK5 receptor. Both then utilise a
common partner (co)-Smad, Smad4, to form a complex that
translocates to the nucleus to alter gene expression [2]. In addition
to Smad signalling, BMPs may act via their receptors through
‘‘Smad independent’’ signalling pathways, including p38 MAPK
(mitogen activated protein kinase), ERK1/2 (extracellular signal
related kinase) and JNK (c-Jun N-terminal kinase) [3]. The
activation of such additional pathways appears to be cell context
specific. Furthermore, there is evidence for crosstalk between these
pathways [4,5].
Abnormalities in BMPR signalling are seen in various clinical
conditions including pulmonary arterial hypertension (PAH). PAH
is a devastating condition associated with significant morbidity and
mortality [6]. Remodelling of small resistance vessels leads to a
progressive increase in pulmonary vascular resistance followed by
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right ventricular failure [7]. Specifically, the genetic defect
underlying the majority (.70%) of cases of heritable PAH is
heterozygous germ-line mutations in BMPR II [8]. Similar
mutations have been found in up to 26% of sporadic cases of
idiopathic PAH [9,10]. Furthermore, a mutation in BMPR II that
leads to a loss of function and a reduction in BMPR II expression
has now been observed in other, more common, forms of human
PAH [11] and in animal models of PAH [12,13]. Indeed, selective
deletion of BMPR II or overexpression of mutant BMPR II in
animal models results in the development of PAH, although
usually at levels milder than in human disease [14]. Expression of
the BMPR type I receptor, ALK3 is also reduced in patients with a
wide variety of conditions causing PAH [15]. These findings
suggest that TGF-b superfamily dysfunction is common to most, if
not all, forms of PAH. Despite this, it remains unclear exactly what
role BMPs themselves play in the pathogenesis of PAH.
In PAH there is also an up-regulation of the endothelin-1 (ET-1)
system. ET-1 is a 21 amino acid peptide which is a vasoconstrictor
and mitogen [6]. In addition, ET-1 has been shown to regulate
endothelial cell migration and angiogenesis [16]. Plasma levels of
ET-1 correlate positively with haemodynamic severity in patients
with PAH and negatively with outcome [17,18]. Furthermore, ET
receptor antagonists (ERAs) reverse pulmonary hypertension and
vascular remodeling in animal models of PAH [19]. Importantly,
ERAs are licensed for the treatment of severe PAH in humans,
with beneficial effects on morbidity and mortality [20]. However,
the mechanisms by which ET-1 levels are elevated in PAH remain
unclear.
We and others have recently shown that BMP-9 stimulates ET-
1 release in vascular endothelial cells, suggesting important
crosstalk between the two systems [21,22]. However, the signalling
pathways involved remain undefined as do the functional
consequences in the vasculature. Indeed, it is uncertain as to
whether such an interaction is relevant to the pathogenesis of
PAH. In this study we sought to answer these questions more fully.
Results
BMP-9 increases ET-1 peptide release and gene
expression in human pulmonary artery endothelial cells
Of the BMPs studied (BMP-2, -4, -6 and -9), only the addition of
BMP-6 and -9 resulted in a significant increase in ET-1 released by
human pulmonary artery endothelial cells (HPAECs) over 24 hrs
(Figure 1A–D). However, the concentrations of BMP-9 which
stimulated ET-1 release were considered more ‘‘physiological’’
than those of BMP-6, and thus further experiments only involved
BMP-9. From the concentration response shown in Figure 1D we
chose a concentration of 1 ng/ml for further experiments [23]. As
a positive control we examined Id-1 expression over a similar
concentration range of BMP-9 (Figure 1E). The results are in
keeping with previous publications [2]. In addition, BMP-9 had a
similar effect on ET-1 release from human lung microvascular
endothelial cells (Text S1 and Figure S1), suggesting the response
is not specific to HPAECs. Importantly, BMP-9 treatment did not
alter cell number over the 24 hrs period, as measured by MTT
and CyQUANT assay (data not shown). Furthermore, BMP-9
stimulated a 2 fold and 3.6 fold increase in prepro ET-1
transcription at 2 hrs and 24 hrs, respectively, as determined by
real-time quantitative RT-PCR (Figure 1F).
BMP-9 stimulated transcription and release of ET-1 in
HPAECs is Smad1 dependent, but independent of Smad4
To define the ignaling pathways leading to ET-1 release by
BMP-9 stimulation, we first investigated Smad protein phosphor-
ylation by western blot. As shown in Figure 2A, Smad1/5 and
Smad2 were phosphorylated after 30 min of BMP-9 stimulation.
To determine the importance of Smad activation, including co-
Smad4, we employed small interfering RNA (siRNA) knock-down.
SiRNA silencing reduced Smad1, 4 and 5 protein levels by more
than 80% compared to DharmaFECT 1 transfection agent alone
(DH1) and negative control siRNA (CP) (Figure 2B). In
comparison to cells treated with BMP-9 and the controls, a
reduction in BMP-9 mediated prepro ET-1 mRNA transcription
was observed in cells transfected with Smad1 siRNA alone
(61.769.8% reduction) or in combination with Smad5 siRNA
(67.568.8%). In contrast, Smad5 siRNA alone reduced the ET-1
response by only 33.769.4% (Figure 2E&F). To confirm
specificity of Smad1 silencing we performed a rescue experiment
with a lentiviral mouse Smad1 construct. The inhibition of BMP-9
stimulated ET-1 release was reversed by the Smad1 construct
(Text S1 and Figure S2A). In addition siRNA silencing of Smad2
had no effect on prepro ET-1 mRNA transcription (data not
shown). Unexpectedly, co-Smad4 siRNA silencing had no effect
on BMP-9 induced prepro ET-1 transcription or mature peptide
release (Figure 2C&D). We did not observe any changes in cell
morphology after transfection of siRNAs over the time period of
the experiments (Text S1 and Figure S3). Overall these results
indicate that BMP-9 induced prepro ET-1 mRNA transcription
(and mature peptide release) is Smad1 dependent, but indepen-
dent the classical Smad signalling cascade via co-Smad4.
p38 MAPK, ERK and JNK phosphorylation in HPAECs:
effect of BMP-9
To investigate whether Smad independent signalling pathways
may be involved in BMP-9 induced ET-1 release from HPAECs we
looked at phosphorylation of ERK1/2, JNK and p38 MAPK at
baseline and following BMP-9 stimulation. Consistent with our
previous findings [24], ERK1/2 was constitutively phosphorylated
at baseline in HPAECs, and showed no detectable change following
BMP-9 stimulation (Figure 3A&B). There was minimal phosphor-
ylation of JNK at baseline with no significant increase after BMP-9
stimulation (Figure 3A&D). Similar to ERK1/2, p38 MAPK was
phosphorylated constitutively at baseline. In contrast, compared to
non-stimulated cells, p38 MAPK phosphorylation was modestly
increased 1.6 fold, 1.4 fold and 1.2 fold at 30 min, 60 min and
120 min respectively, following addition of BMP-9 (Figure 3A&C).
Regulation of ET-1 by BMP-9 in HPAECs is p38 MAPK
dependent
To determine whether ET-1 regulation by BMP-9 was
dependent on p38 MAPK, we used the specific pharmacological
inhibitor SB203580. SB203580 (10 mM) completely inhibited
BMP-9 induced prepro ET-1 mRNA transcription and ET-1
peptide release (Figure 4A&B). There was no change in cell
viability as determined by MTT assay (results not shown). To
further confirm these finding we used an alternative, highly
specific, p38 MAPK inhibitor BIRB796 (1 mM) and the upstream
TAK-1 inhibitor (5Z)-7-Oxozeanol (0.5 mM) at concentrations
considered to be specific to inhibition of the MAPK pathway
[25,26]. Both inhibitors abolished BMP-9 stimulated ET-1 release
from HPAECs over a 24 hrs period (Figure 4D&E). The ERK1/2
inhibitor UO126 (1–10 mM) caused a small non-significant
reduction in ET-1 peptide release after BMP-9 stimulation, but
a similar reduction was seen with baseline ET-1 levels (Figure 4C).
Finally, we found that the JNK inhibitor (SP600125) was toxic to
HPAECs as determined by MTT (data not shown) and therefore
the results are not included.
BMP-9 Induced ET-1 Release in Endothelium Function
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Figure 1. ET-1 release in response to BMPs and ET-1 mRNA expression by BMP-9 stimulation. HPAECs were grown to confluence on 96-
well plates or 6-well plates and starved for 16 hrs. Cells were then stimulated with various concentrations of BMP-2, n = 4 (A), BMP-4, n = 7 (B), BMP-6,
n = 5 (C) or BMP-9, n = 6 (D). Supernatants were collected at 24 hrs of treatment and ET-1 level assayed by ELISA. RNA was extracted from cells treated
with increasing concentration of BMP-9 for 24 hrs. Id-1 gene expression was determined by qRT-PCR and normalised to the average of 2 housekeeping
genes and shown relative to expression of non-stimulated controls, n = 3 (E). RNA was extracted from cells treated with 1 ng/ml BMP-9 at 2 hrs and
24 hrs time points and ET-1 gene expression determined by qRT-PCR. ET-1 was normalised to the average of 2 housekeeping genes and shown relative
to expression of non-stimulated controls at 2 hr and 24 hs, n = 4 (F). Data are presented as mean 6 SEM. *p,0.05, **p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0030075.g001
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BMP-9 induced ET-1 release is only partially mediated by
ALK1 and BMPR II receptors. Basal prepro ET-1 mRNA
transcription and ET-1 release is increased by BMPR II
knock-down
ALK1 and BMPR II are the main receptors that bind BMP-
9 in endothelial cells [2]. To establish the role of these
receptors in BMP-9 stimulated ET-1 release in HPAECs we
performed siRNA knock-down of the receptors. SiRNA knock-
down efficiently reduced ALK1 and BMPR II protein
expression by greater than 80% (Figure 5A). Knock-down of
ALK1 or BMPR II resulted in a moderate but incomplete
reduction in BMP-9 stimulated ET-1 release (Figure 5B). To
confirm specificity of BMPR II silencing we performed a
rescue experiment with a lentiviral mouse BMPR II construct.
The inhibition of BMP-9 stimulated ET-1 release was reversed
by the BMPR II construct (Text S1 and Figure S2B). In these
experiments it appeared that there was an increase in basal
release of ET-1 with BMPR II knock-down. Therefore we
repeated these experiments and also looked at the effect of
BMPR II knock-down on prepro ET-1 mRNA transcription.
Consistent with the earlier results we found a significant
increase in prepro ET-1 mRNA transcription (47.468.94%
increase over control siRNA (CP)) and also a significant
increase in mature peptide release (55.16615.34% increase
over control siRNA(CP)) (Figure 5C&D).
Figure 2. Effects of Smad signalling pathway on BMP-9 induced prepro ET-1 mRNA transcription and ET-1 release. HPAECs were
grown to confluence in 6-cm dishes, starved for 16 hrs and then stimulated with BMP-9 (1 ng/ml). Phosphorylation of Smad1/5 and Smad2 were
determined by western blot (A). After transfected with Smad4 specific or non-targeting siRNA and starved for 16 hs, HPAECs were stimulated with
BMP-9 (1 ng/ml). The knockdown efficiency was determined by western blotting (B). After siRNA treatment and BMP-9 stimulation, supernatants and
cells were collected at 24 hrs (6-well plates) for determination of ET-1 peptides by ELISA, n = 4 (C) and mRNA levels by qRT-PCR, n = 4 (D). HPAECs
were transfected with Smad1, Smad5 or non-targeting siRNA. Specific Smad1 and Smad5 knockdown were confirmed by qRT-PCR (not shown) and
western blotting (E). After siRNA treatment, HPAECs were starved and stimulated with BMP-9 (1 ng/ml) for 24 hrs. RNA was extracted and gene
expression determined by qRT-PCR. ET-1 was normalised to b-actin and is expressed relative to cells exposed to DH1 only, n = 5 (F). Data are
presented as mean 6 SEM. **p,0.01.
doi:10.1371/journal.pone.0030075.g002
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Role of endogenously released ET-1 in BMP-9 induced
tubule formation
To investigate whether BMP-9 stimulated ET-1 release had a
functional role in HPAECs we looked at BMP-9 stimulated tubule
formation using matrigel. After 4 hrs of BMP-9 stimulation,
HPAECs formed a complex tubule network as shown in Figure 6A.
BMP-9 stimulated tubule formation was inhibited by the ETA
receptor antagonist BQ-123 (50 nM), but not by the ETB receptor
antagonist BQ-788 (50 nM) (Figure 6A&B). Both compounds alone
had no or little effect on HPAEC tubule formation (Figure 6A&B).
To further support our finding of a role for endogenously released
ET-1 in BMP-9 stimulated tubule formation, we investigated the
effect of p38 MAPK inhibition using BIRB796 (1 mM) and Smad1
and 4 knock-down. In line with our previous results, p38 MAPK
inhibition and Smad1 knock-down inhibited BMP-9 induced tubule
formation, whilst knock-down of Smad4 had no effect (Figure 7).
Role of endogenously released ET-1 in BMP-9-induced
migration
To further investigate a functional role of BMP-9 stimulated
endogenous ET-1 release, we investigated the effect of BMP-9 on
HPAEC migration using the Transwell migration assay. After
4 hrs BMP-9 (1 ng/ml) alone inhibited endothelial cell migration
by 56.862.9% versus medium alone. This inhibition was almost
entirely abolished by BQ-123, but not by BQ-788; neither
inhibitor alone affecting migration (Figure 8A&B).
Discussion
The main findings of this study are: (1) BMP-9 induced prepro
ET-1 mRNA transcription and mature peptide release in
HPAECs are dependent on Smad1 signalling but independent of
co-Smad4; (2) p38 MAPK signalling is necessary for BMP-9
induced ET-1 release; (3) BMP-9 stimulated ET-1 release is only
partially mediated through BMPR II and ALK1; (4) BMPR II
knock-down increases basal prepro ET-1 mRNA transcription and
mature peptide release and (5) BMP-9 induced endogenous ET-1
release is involved in BMP-9 stimulated HPAEC tubule formation
and inhibition of HPAEC migration. Taken together these results
support a role for BMP-9 induced ET-1 release in endothelial cell
stability but not in the pathogenesis of PAH. However, BMPR II
dysfunction appears important in regulating basal ET-1 levels and
so may be important in the pathogenesis of PAH.
Although we and others have demonstrated BMP-9 induced
ET-1 release from endothelial cells, this is the first study to
determine the signalling pathways involved [21,22]. Unsurpris-
ingly, addition of BMP-9 to HPAECs resulted in phosphorylation
of Smad1/5 and Smad2/3 pathways. However, after successful
knock-down of the ‘common pathway’ Smad4 (confirmed by at
least 80% knock-down of mRNA and protein) we found no effect
on either prepro ET-1 mRNA or mature peptide release, whereas
Smad1 knock-down consistently attenuated the induction of
prepro ET-1 mRNA transcription by BMP-9. Furthermore, Smad
2 knock-down had no effect on prepro ET-1 mRNA transcription.
Figure 3. ERK1/2, JNK and p38 MAPK phosphorylation in HPAECs stimulated with BMP-9. HPAECs were grown to confluence in 6-cm
dishes, starved for 16 hrs and then stimulated with BMP-9 (1 ng/ml). Phosphorylation of ERK1/2, JNK and p38 MAPK were determined by western blot
(A), and quantified by densitometry (B, C and D). Data are presented as mean 6 SEM. n = 3, #p.0.05; *p,0.05, one -way ANOVA, control vs. BMP-9
stimulation.
doi:10.1371/journal.pone.0030075.g003
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Taken together, our results would suggest that BMP-9 stimulated
ET-1 release does not use classical Smad signalling, but instead is
dependent on Smad1 and independent of Smad4. Indeed, Smad4
independent signalling has been previously reported. For example,
TGF-b mediated differentiation of haemopoietic/progenitor stem
cells is dependent on binding of transcriptional intermediary factor
1c (TIFI 1c) to a phosphorylated Smad2/3 complex [27] whereas
TGF-b mediated keratinocyte proliferation and differentiation
involves Smad4 independent binding of IkB kinase (IKK)a to
Smad2/3 [27,28]. Furthermore, BMP-4 mediated sympathetic
nervous system development in the mouse embryo is partly
dependent on Smad4 independent, Smad 1/5/8 dependent
activation of the paired-like homeobox transcription factor,
Phox2b [29].
We found that both transcription of prepro ET-1 mRNA and
release of mature peptide are dependent on p38 MAPK
phosphorylation as determined by pharmacological inhibition
using the compounds SB203580 and BIRB796, as well as
upstream inhibition of the pathway using the TAK-1 inhibitor
(5Z)-7-Oxozeanol. Indeed, MAPKs have long been implicated in
TGF-b1 and BMP signalling; BMP-2, -4, -6 and -7 can signal
through p38 MAPK dependent, Smad independent pathways
[30,31]. We found that HPAECs had a constitutive level of p38
MAPK phosphorylation with only a minor increase in phosphor-
ylation with BMP-9 stimulation. We interpret these results as the
need for a constitutive level of p38 MAPK phosphorylation for
Smad1 induced prepro ET-1 mRNA transcription; BMP-9
induced increase in p38 MAPK phosphorylation per se is unlikely
to be relevant. Of course, we realize a limitation in our
pharmacological approach in that SB203580, BIRB796 and the
TAK-1 inhibitor may be inhibiting alternative kinase pathways
[32,33] in addition to p38 MAPK, which are involved in co-
operation with Smad1 driven signaling. However, BIRB796 has
recently been reported to be highly specific for p38 MAPK, with
an affinity greater than ten times than that for other kinases [26].
Crosstalk between MAPKs and Smad networks has been
previously reported in various cell types. Overexpression of Smad6
or Smad7 can inhibit BMP-2 induced p38 MAPK phosphoryla-
tion, whilst receptor-Smads have MAPK consensus sites allowing
differential phosphorylation by MAPKs [4]. In a lung cancer cell-
line model, p38 MAPK activation was required for full activation
of the transcriptional potential of Smad1/5, after treatment with
BMP-4. Importantly, and of relevance to our study, SB203580 did
not affect phosphorylation of Smad 1/5 (although not directly
tested in our study). The mechanism involved p38 MAPK
dependent co-operation of the transcription factor Sp1 with
Smad1/5 on P16 and P21 promoters [5]. We would therefore
hypothesize that a similar mechanism may be occurring in BMP-9
Figure 4. Effects of p38 MAPK and ERK1/2 inhibition on BMP-9 stimulated prepro ET-1 mRNA transcription and ET-1 release. HPAECs
were grown to confluence, starved for 16 hrs and then pre-incubated with 1–10 mM SB203580, 1–10 mM UO126, 0.5 mM (5Z)-7-Oxozeanol or 1 mM
BIRB796 for 60 min before adding BMP-9 (1 ng/ml) for another 24 hrs. Supernatants and cells were collected for determination of ET-1 by ELISA n=4
(A, C, D, E), and prepro ET-1 mRNA levels by qRT-PCR, n = 3 (B). Data are presented as mean 6 SEM. #p.0.05; * p,0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0030075.g004
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stimulated HPAECs. In further support of this mechanism,
Rodriguez-Pascual et al have demonstrated that TGF-b stimulated
prepro ET-1 mRNA transcription in bovine aortic endothelial
cells requires co-operation of Smad2/3 and AP-1 on the prepro
ET-1 promoter [34]. Finally, Morikawa et al. have reported for the
first time Smad1/5 chromatin immune-precipitation (ChIP)-
sequencing in human umbilical vein endothelial cells (HUVECs).
It appears that Smad1/5 binding occurs mainly outside known
target gene promoter regions. The authors identified, for the first
time, a Smad1/5 binding motif in mammals (GC-SBE). They
found that both GC-SBE and the canonical smad binding
elements (SBE) affect binding affinity for the Smad complex
[35]. The exact mechanisms involved in BMP-9 stimulated ET-1
release in HPAECs including Smad1 CHIP analysis are now the
subject of further investigation.
We also demonstrated that BMP-9 induction of ET-1 release is
only partially mediated by the type I receptor ALK1 and the type
II receptor BMPR II. These findings are not surprising given
previous studies suggesting redundancy of type I and type II
receptors in endothelial cells. Indeed, Upton et al have recently
demonstrated that in HPAECs, BMP-9 can signal through ALK1/
BMPR II or ALK1/Actr II complexes, to activate Smad1/5 and
Smad2 [2]. Our results would suggest that on knock-down of
BMPR II, signalling may proceed via Actr II, although we did not
directly look for this in the present study. In addition, and of
potential importance, we found that knock-down of BMPR II
caused a significant increase in basal ET-1 release and prepro ET-
1 mRNA expression in HPAECs. This finding is potentially
important as loss of BMPR II function appears widespread in
PAH, where plasma and tissue ET-1 levels are also elevated
[19,36]; these findings suggest a mechanism by which ET-1 is
elevated in PAH. In support of our findings is the recent
observation by Talati et al that macrophages from patients with
BMPR II mutations have an up-regulated ET-1 system, associated
with reduction in ETB receptor levels [37]. Clearly, increased ET-
1 production by the vascular endothelial cells is likely to be more
relevant to overall vascular remodeling, but concordance in these
findings supports a clinically relevant interaction between BMPR
II dysfunction and the ET-1 system and warrants further
investigation. Furthermore, the partial dependence on BMPR II
Figure 5. Effects of ALK1 and BMPR II siRNA on BMP-9 induced ET-1 release. HPAECs were transfected with ALK1, BMPR II specific or non-
targeting siRNA. Cells were starved for 16 hrs and stimulated with BMP-9 (1 ng/ml) for 24 hrs. Knock-down efficiency was determined by western
blotting. The arrows denote ALK1 (62 kDa) and BMPR II (doublet 190 kDa and 145 kDa) (A). Supernatants were collected at 24 hrs post-stimulation
for determination of ET-1 release by ELISA (B&C). RNA was extracted from HPAECs treated with BMPR II specific siRNA and gene expression was
determined by qRT-PCR (D). Data are presented as Mean 6 SEM, n= 4. #p.0.05; **p,0.01.
doi:10.1371/journal.pone.0030075.g005
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receptor function for BMP-9 induced, increased ET-1 release,
would suggest that BMP-9 induced ET-1 release is not the
mechanism for raised ET-1 production by endothelial cells in
human PAH.
We found that BMP-9 enhanced tubule formation and inhibited
cell migration in HPAECs, supporting the role for BMP-9 in
enhancing vascular stability [23]. Both of these effects were
dependent on endogenous ET-1 acting via the ETA receptor.
Further support for endogenous ET-1 mediating these effects was
demonstrated by dependence on p38 MAPK and Smad1
pathways (but not Smad 4) for BMP-9 stimulated tubule
formation, in line with our previous signalling results. Although
BMP-9 induced tubule formation is a novel observation, BMP-9
does promote vessel formation from allantoic explants at low
concentrations (4 ng/ml) [38], whilst inhibiting endothelial
sprouting from embryoid bodies at higher concentrations (10
Figure 6. Effect of BMP-9 induced ET-1 release on HPAEC tubule formation. HPAECs were seeded onto matrigel and tubule formation
capacity analysed as described in the materials and methods section. Representitive images of 3 independent experiments of tubule formation are
shown in (A). The average length of the tublule networks in the various conditions shown was quantified using Image J (NIH) and represented
graphically in (B). Data are presented as mean 6 SEM, n= 3. **p,0.01.
doi:10.1371/journal.pone.0030075.g006
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and 100 ng/ml), suggesting a concentration dependent effect [23].
Equally, BMP-9 has been shown to both inhibit and induce cell
proliferation [39,40], which may again depend on the concentra-
tion used, as well as cell type differences [2,39]. Indeed, in our
system using lower (and more physiological) BMP-9 concentra-
tions, we found no effect on HPAEC proliferation. Finally, other
BMPs such as BMP-2 and BMP-4 can also stimulate tubule
formation [41]. Our finding of BMP-9 induced inhibition of
endothelial cell migration confirms the findings of Lee et al. In their
study BMP-9 inhibition of migration was ALK1 dependent and
enhanced by CK2b, the regulatory subunit of protein kinase CK2
[42]. Overall, our data and that of others, suggest that BMP-9 is
important in processes pertinent to new vessel formation and
stabilisation. Indeed, disruption in ALK1 mediated signalling in
endothelial cells is known to cause disordered angiogenesis, as seen
in hereditary haemorrhagic telangiectasia (HHT) where mutation
in ALK1 has been described [43,44]. Disruption of BMP-9
signalling through ALK1 may therefore be important in the
development of HHT related vascular changes.
Whereas ET-1 has been shown to promote endothelial tubule
formation [45,46], in agreement with our findings, it is also
generally known as a chemo-attractant, promoting migration [46–
48]. Furthermore, migration of HUVECs, stimulated by ascitic
fluid from patients with ovarian cancer (known to contain high
levels of ET-1 and vascular endothelial growth factor (vEGF), was
more effectively blocked by the ETB receptor antagonist, BQ-788
(55%) than the ETA receptor antagonist, BQ-123 (25%) [16]. In
our cells, the opposite was found, in that migration was ETA
receptor dependent. However, in support of our findings,
Rodriguez-Pascual et al. reported in bovine aortic endothelial cells
Figure 7. Effect of p38 MAPK inhibition and Smad1/Smad4 knock-down on BMP-9 induced HPAEC tubule formation. HPAECs or
HPAECs transfected with negative control (CP), Smad1 and Smad4 siRNA were seeded onto matrigel and tubule formation capacity analysed as
described in the materials and methods section. Representitive images of 3 independent experiments of tubule formation are shown in (A&B). The
average length of the tublule networks in the various conditions shown was quantified using Image J (NIH) and represented graphically in (C). Data
are presented as mean 6 SEM, n = 3. ***p,0.001.
doi:10.1371/journal.pone.0030075.g007
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Figure 8. Effect of BMP-9 induced ET-1 on HPAEC migration. HPAECs were seeded onto transwell inserts and migration determined as
described in the materials and methods section. Representitive images of 3 independent experiments of cells (nuclei identified with DAPI staining)
migrated to the lower chamber are shown in (A). Migrated cells, under the conditions described shown, were counted and expressed graphically, as
the percentage of the control in (B). Data are presented as mean 6 SEM, n= 3. **p,0.01.
doi:10.1371/journal.pone.0030075.g008
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that TGF-b had anti-migratory actions, due to endogenous ET-1
production, being reversed by the mixed endothelin receptor
antagonist bosentan [49]. Furthermore, in that study, the anti-
migratory effect of ET-1 was dependent on active TGF-b
signaling, suggesting that ET-1 was acting in conjunction with
other TGF-b stimulated mediators. It is possible that a similar
situation exists for BMP-9 in our system. Finally, although it is
generally believed that the ETA receptor is mainly active on
vascular smooth muscle and not endothelial cells, there are several
recent papers reporting ETA expression and activity in endothelial
cells of various origins, including pulmonary vascular endothelial
cells in patients with idiopathic PAH [50–54]. Indeed, we
confirmed the expression of ETA and ETB receptor mRNA in
HPAECs, although no change in mRNA expression was found
with BMP-9 stimulation (data not shown).
In conclusion, our results demonstrate that BMP-9 induced ET-
1 release in HPAECs is partially mediated through the ALK1/
BMPR II receptor complex, in a Smad1 and p38 MAPK
dependent manner. BMP-9 also promotes tubule formation, and
inhibits HPAEC migration, both effects blocked by ETA receptor
antagonism, suggesting an important functional role for BMP-9
stimulated endogenous ET-1. These findings support the concept
of BMP-9 being a circulating factor affecting angiogenesis and
endothelial stabilisation. However, the dependence of this effect on
BMPR II signalling argues against an important role for BMP-9 as
a source of increased endothelial ET-1 production in human PAH.
In fact, such signalling may be more relevant for diseases such as
HHT. Importantly, BMPR II dysregulation per se may increase
basal endothelial cell ET-1 release, suggesting a potential role in
the pathogenesis of PAH, and warranting further investigation.
Materials and Methods
Cell culture
Primary human pulmonary artery endothelial cells (HPAECs:
Lonza, Wokingham, UK) maintained in complete endothelial cell
growth medium-2 (EGM-2) were used at passages 3–8.
Kinase pathways inhibition
After quiescence for 16 hrs in EGM-2 without hydrocortisone
and 0.1% FBS, HPAECs were pre-treated with the mitogen
activated protein kinase (MEK)1/2/ERK inhibitor UO126 (1, 3
and 10 mM), the JNK inhibitor, SP600125 (1, 3 and 10 mM), the
p38MAPK inhibitors, SB203580 (1, 3 and 10 mM) (Cell Signaling,
Beverley, MA, USA) and BIRB796 (1 mM), or the transforming
growth factor-b activating kinase (TAK-1) inhibitor (5Z)-7-
Oxozeanol (0.5 mM. Calbiochem, San Diego, CA, USA), or
vehicle controls for 1 hr. BMP-9 (R&D Systems, Abingdon, UK)
was added to give a final concentration of 1 ng/ml for a further
24 hrs.
Endothelin ELISA
After quiescence for 16 hrs in EGM-2 without hydrocortisone
and 0.1% FBS, HPAECs were treated with either BMP-2, -4, -6 or
-9 for 24 hrs. After treatment, media were collected and cleared by
centrifugation at 10,0006g for 1 min. ET-1 concentration in
supernatants was measured by enzyme-linked immunosorbent
assay (ELISA) according to the manufacturer’s instruction (R&D
Systems, Abingdon, UK) as previously described [55].
Cell Proliferation
After aspiration of supernatants, cell viability was determined by
MTT assay or cells were frozen at 280uC and analyzed by the
CyQUANT assay (Sigma-Aldrich, Poole, UK), as per the
manufacturer’s protocol.
Small interfering RNA silencing
Small interfering RNA knock-down was carried out as described
previously [2]. In brief, HPAECs were transfected with 20 nM of
siRNA duplexes for Smad4 or 10 nM for ALK1, Smad1, Smad2,
Smad5 (OnTARGET-Plus siGenome, DharmaconTM, Lafayette,
CO, USA) or BMPR II (Dharmacon SmartpoolH), or non-
targeting control pool siRNA in complex with DharmaFECT1TM
transfection reagent (DH1) (4 ml/well for 6-well plate or 8.75 ml/
dish for 6-cm dish) in OptiMem I (Invitrogen, Paisley, UK) for
4 hrs.
RNA extraction and real time qRT-PCR
Total RNA (1 mg) was transcribed to cDNA using L-AMV
reverse transcriptase (Invitrogen, Paisley, UK) or a high capacity
cDNA reverse transcription kit (Applied Biosystems, Paisley, UK)
according to the manufacturer’s instructions. Real-time quantita-
tive PCR was performed using SYBR green master mix (Qiagen,
West Sussex, UK) or SYBRH Green JumpstartTM Taq Ready-
mixTM (Sigma, Poole, UK) on a Corbett Rotor-Gene 6000
(Qiagen, West Sussex, UK) or an ABI StepOne PlusTM (Applied
Biosystems, Paisley, UK). The relative expression of target genes
was quantified using the DDCt method normalized to the average
expression of two housekeeping genes (b-actin and GUSB) [56].
The sequences for ET-1, ALK1, BMPR II, Smad1, Smad5,
Smad4, Id-1, b-actin and GUSB primers are described previously
[2,57].
Immunoblotting
20 mg of total protein (30 mg for p38 MAPK and Smad2) from
whole cell lysates was separated on SDS-PAGE and transferred to
nitrocellulose membranes or polyvinylidene fluoride membranes
(GE Healthcare, Buckinghamshire, UK). Membranes were first
probed with anti-phospho-p38, phospho-ERK1/2, phospho-JNK,
phospho-Smad1/5, phospho-Smad2, Smad1, Smad4, Smad5
(Cell Signaling, Beverley, MA, USA), BMPR II (BD Bioscience,
Oxford, UK) or ALK1 (kindly provided by Professor D.A.
Marchuk, Duke University Medical Center) then stripped with
50 mM Tris, pH 8.0, 150 mM NaCl, 2%SDS and 100 mM b-
mecaptoethanol for 1 hr at 55uC, and re-probed with total p38
MAPK, ERK1/2, JNK, Smad1/5 and Smad2 (Cell Signaling,
Beverley, MA, USA), a-tubulin or b-actin (Sigma, Poole, UK) to
confirm equal protein loading). Membranes were developed using
ECL (GE Healthcare, Buckinghamshire, UK). The intensity of the
bands was quantified using Image J (NIH).
Tubule formation assay
HPAECs (56104/well) or HPAECs transfected with siRNA
(CP, Smad1 or Smad4, 68 hrs post-transfection) were seeded on 8-
well slides coated with growth factor reduced matrigel (200 ml/
well: BD Biosciences, Oxford, UK) and incubated for 4 hrs in the
presence or absence of BMP-9 (1 ng/ml), and various concentra-
tions of the ETA inhibitor BQ-123 or the ETB inhibitor, BQ-788
(10 nM–2 mM, Tocris Bioscience, Bristol, UK), or 1 mM
BIRB796.
Cell migration assay
Serum starved HPAECs (56104 cells) were added to the upper
chamber of a 24-well insert (8 mm pore, TranswellH) pre-coated
with gelatin (20 mg/insert) in the presence of BQ-123, BQ-788 or
vehicle control. Starvation medium (600 ml) with or without BMP-
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9 (1 ng/ml), BQ-123, BQ-788 or vehicle control was added to the
lower chamber. Plates were incubated at 37uC for 4 hrs. After
incubation, cells in the upper chambers were removed with cotton
buds. Cells on the lower chamber membranes were fixed with
3.7% formaldehyde for 5 min, the membrane was then cut and
mounted between a slide and a coverslip in ProLong antifade
mounting solution containing DPI (Invitrogen, Paisley, UK).
Images were taken using a Zeiss Fluorescence microscope.
Statistical analysis
Experimental data are presented as mean 6 SEM. BMP dose
response experiments were analyzed using Friedman’s non-
parametric repeated measures test with Dunn’s post test
correction. The remaining data were analyzed using Kruskal-
Wallis non-parametric analysis with Dunn’s Multiple Comparison
Test or two-way ANOVA with Bonferroni Post test, using
GraphPad Prism4.
Supporting Information
Figure S1 ET-1 release from HLMVECs in response to
BMP-9 stimulation. HLMVECs were grown to confluence on
96-well plates and starved for 16 hrs. Cells were then stimulated
with increasing concentrations of BMP-9. Supernatants were
collected at 24 hrs of treatment and ET-1 level assayed by ELISA.
Data are presented as mean 6 SEM. n= 6 * p,0.05.
(TIF)
Figure S2 Re-expression of Smad1 and BMPR II in
HPAECs rescues the effect of Smad1 and BMPR II siRNA
silencing respectively. HPAECs were grown to confluence on
96-well plates and transfected with siRNAs for 4 hrs and left over-
night. Cells were then infected with viral particles encoding mouse
Smad1 (A), BMPR II (B) or GFP for 16 hrs. After viral
transduction, cells were starved for a further 16 hrs and then
stimulated with 1 ng/ml of BMP-9 for 24 hrs. Supernatants were
then collected and ET-1 level assayed by ELISA. Data are
presented as mean 6 SEM, n= 3. *** p,0.001, # p.0.05.
(TIF)
Figure S3 Effects of CP, DH1, Smad1 and BMPR II
siRNA transfection on the morphology of HPAECs.
HPAECs were seeded onto coverslips and transfected with siRNAs
as described in the materials and methods section. Representitive
cell morphology is shown. Red: F-actin cytoskeleton identified
with TRITC-phalloidin staining; Blue: nuclei identified with DAPI
staining.
(TIF)
Text S1 Materials and methods.
(DOC)
Author Contributions
Conceived and designed the experiments: SJW MJDG NWM DS PDU
IMA. Performed the experiments: JESP DS PDU PdeS RJD. Analyzed the
data: JESP DS PDU IMA. Wrote the paper: SJW DS MJDG JESP.
References
1. Zeng S, Chen J, Shen H (2010) Controlling of bone morphogenetic protein
signaling. Cell Signal 22: 888–893.
2. Upton PD, Davies RJ, Trembath RC, Morrell NW (2009) Bone morphogenetic
protein (BMP) and activin type II receptors balance BMP9 signals mediated by
activin receptor-like kinase-1 in human pulmonary artery endothelial cells. J Biol
Chem 284: 15794–15804.
3. Huang MS, Morony S, Lu J, Zhang Z, Bezouglaia O, et al. (2007) Atherogenic
phospholipids attenuate osteogenic signaling by BMP-2 and parathyroid
hormone in osteoblasts. J Biol Chem 282: 21237–21243.
4. Kimura N, Matsuo R, Shibuya H, Nakashima K, Taga T (2000) BMP2-induced
apoptosis is mediated by activation of the TAK1-p38 kinase pathway that is
negatively regulated by Smad6. J Biol Chem 275: 17647–17652.
5. Su D, Peng X, Zhu S, Huang Y, Dong Z, et al. (2010) Role of p38 MAPK
pathway in BMP4-mediated Smad-dependent premature senescence in lung
cancer cells. Biochem J 433: 333–343.
6. Shao D, Park JE, Wort SJ (2011) The role of endothelin-1 in the pathogenesis of
pulmonary arterial hypertension. Pharmacol Res 63: 504–511.
7. Price LC, Montani D, Tcherakian C, Dorfmuller P, Souza R, et al. (2011)
Dexamethasone reverses monocrotaline-induced pulmonary arterial hyperten-
sion in rats. Eur Respir J 37: 813–822.
8. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA, 3rd, et al.
(2000) Heterozygous germline mutations in BMPR2, encoding a TGF-beta
receptor, cause familial primary pulmonary hypertension. Nat Genet 26: 81–84.
9. Thomson JR, Machado RD, Pauciulo MW, Morgan NV, Humbert M, et al.
(2000) Sporadic primary pulmonary hypertension is associated with germline
mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta
family. J Med Genet 37: 741–745.
10. Machado RD, Pauciulo MW, Thomson JR, Lane KB, Morgan NV, et al. (2001)
BMPR2 haploinsufficiency as the inherited molecular mechanism for primary
pulmonary hypertension. Am J Hum Genet 68: 92–102.
11. Atkinson C, Stewart S, Upton PD, Machado R, Thomson JR, et al. (2002)
Primary pulmonary hypertension is associated with reduced pulmonary vascular
expression of type II bone morphogenetic protein receptor. Circulation 105:
1672–1678.
12. Rondelet B, Kerbaul F, Van Beneden R, Motte S, Fesler P, et al. (2004)
Signaling molecules in overcirculation-induced pulmonary hypertension in
piglets: effects of sildenafil therapy. Circulation 110: 2220–2225.
13. Takahashi H, Goto N, Kojima Y, Tsuda Y, Morio Y, et al. (2006)
Downregulation of type II bone morphogenetic protein receptor in hypoxic
pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 290: L450–458.
14. Hong KH, Lee YJ, Lee E, Park SO, Han C, et al. (2008) Genetic ablation of the
BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary
arterial hypertension. Circulation 118: 722–730.
15. Du L, Sullivan CC, Chu D, Cho AJ, Kido M, et al. (2003) Signaling molecules in
nonfamilial pulmonary hypertension. N Engl J Med 348: 500–509.
16. Salani D, Di Castro V, Nicotra MR, Rosano L, Tecce R, et al. (2000) Role of
endothelin-1 in neovascularization of ovarian carcinoma. Am J Pathol 157:
1537–1547.
17. Cacoub P, Dorent R, Nataf P, Carayon A, Riquet M, et al. (1997) Endothelin-1
in the lungs of patients with pulmonary hypertension. Cardiovasc Res 33:
196–200.
18. Yoshibayashi M, Nishioka K, Nakao K, Saito Y, Matsumura M, et al. (1991)
Plasma endothelin concentrations in patients with pulmonary hypertension
associated with congenital heart defects. Evidence for increased production of
endothelin in pulmonary circulation. Circulation 84: 2280–2285.
19. Humbert M, Simonneau G (2005) Drug Insight: endothelin-receptor antagonists
for pulmonary arterial hypertension in systemic rheumatic diseases. Nat Clin
Pract Rheumatol 1: 93–101.
20. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, et al. (2002) Bosentan
therapy for pulmonary arterial hypertension. N Engl J Med 346: 896–903.
21. Star GP, Giovinazzo M, Langleben D (2010) Bone morphogenic protein-9
stimulates endothelin-1 release from human pulmonary microvascular endothe-
lial cells A potential mechanism for elevated ET-1 levels in pulmonary arterial
hypertension. Microvasc Res 80: 5.
22. Park J, Upton PD, De Souza P, Davies RJ, Morrell NW, et al. (2010) Bone
Morphogenetic Protein (BMP)-9 Increases Endothelin (ET)-1 Release By
Human Pulmonary Artery Endothelial Cells Via A MAPK Dependent Pathway.
Am J Respir Crit Care Med 181: A5240.
23. David L, Mallet C, Keramidas M, Lamande N, Gasc JM, et al. (2008) Bone
morphogenetic protein-9 is a circulating vascular quiescence factor. Circ Res
102: 914–922.
24. Yang X, Long L, Southwood M, Rudarakanchana N, Upton PD, et al. (2005)
Dysfunctional Smad signaling contributes to abnormal smooth muscle cell
proliferation in familial pulmonary arterial hypertension. Circ Res 96:
1053–1063.
25. Park JK, Fischer R, Dechend R, Shagdarsuren E, Gapeljuk A, et al. (2007) p38
mitogen-activated protein kinase inhibition ameliorates angiotensin II-induced
target organ damage. Hypertension 49: 481–489.
26. Mayer RJ, Callahan JF (2006) p38 MAP kinase inhibitors: A future therapy for
inflammatory diseases. Drug Discovery Today: Therapeutic Strategies 3: 6.
27. He W, Dorn DC, Erdjument-Bromage H, Tempst P, Moore MA, et al. (2006)
Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the
TGFbeta pathway. Cell 125: 929–941.
28. Descargues P, Sil AK, Sano Y, Korchynskyi O, Han G, et al. (2008) IKKalpha is
a critical coregulator of a Smad4-independent TGFbeta-Smad2/3 signaling
pathway that controls keratinocyte differentiation. Proc Natl Acad Sci U S A
105: 2487–2492.
29. Mukhopadhyay A, McGuire T, Peng CY, Kessler JA (2009) Differential effects
of BMP signaling on parvalbumin and somatostatin interneuron differentiation.
Development 136: 2633–2642.
BMP-9 Induced ET-1 Release in Endothelium Function
PLoS ONE | www.plosone.org 12 January 2012 | Volume 7 | Issue 1 | e30075
30. Yang X, Lee PJ, Long L, Trembath RC, Morrell NW (2007) BMP4 induces
HO-1 via a Smad-independent, p38MAPK-dependent pathway in pulmonary
artery myocytes. Am J Respir Cell Mol Biol 37: 598–605.
31. Nohe A, Hassel S, Ehrlich M, Neubauer F, Sebald W, et al. (2002) The mode of
bone morphogenetic protein (BMP) receptor oligomerization determines
different BMP-2 signaling pathways. J Biol Chem 277: 5330–5338.
32. Bain J, McLauchlan H, Elliott M, Cohen P (2003) The specificities of protein
kinase inhibitors: an update. Biochem J 371: 199–204.
33. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, et al. (2007) The selectivity of
protein kinase inhibitors: a further update. Biochem J 408: 297–315.
34. Rodriguez-Pascual F, Reimunde FM, Redondo-Horcajo M, Lamas S (2004)
Transforming growth factor-beta induces endothelin-1 expression through
activation of the Smad signaling pathway. J Cardiovasc Pharmacol 44 Suppl
1: S39–42.
35. Morikawa M, Koinuma D, Tsutsumi S, Vasilaki E, Kanki Y, et al. (2011) ChIP-
seq reveals cell type-specific binding patterns of BMP-specific Smads and a novel
binding motif. Nucleic Acids Res 39: 8712–8727.
36. Morrell NW (2006) Pulmonary hypertension due to BMPR2 mutation: a new
paradigm for tissue remodeling? Proc Am Thorac Soc 3: 680–686.
37. Talati M, West J, Blackwell TR, Loyd JE, Meyrick B (2010) BMPR2 mutation
alters the lung macrophage endothelin-1 cascade in a mouse model and patients
with heritable pulmonary artery hypertension. Am J Physiol Lung Cell Mol
Physiol 299: L363–373.
38. Suzuki Y, Ohga N, Morishita Y, Hida K, Miyazono K, et al. (2010) BMP-9
induces proliferation of multiple types of endothelial cells in vitro and in vivo.
J Cell Sci 123: 1684–1692.
39. David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S (2007) Identification of
BMP9 and BMP10 as functional activators of the orphan activin receptor-like
kinase 1 (ALK1) in endothelial cells. Blood 109: 1953–1961.
40. Scharpfenecker M, van Dinther M, Liu Z, van Bezooijen RL, Zhao Q, et al.
(2007) BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell
proliferation and VEGF-stimulated angiogenesis. J Cell Sci 120: 964–972.
41. Rothhammer T, Bataille F, Spruss T, Eissner G, Bosserhoff AK (2007)
Functional implication of BMP4 expression on angiogenesis in malignant
melanoma. Oncogene 26: 4158–4170.
42. Lee NY, Haney JC, Sogani J, Blobe GC (2009) Casein kinase 2beta as a novel
enhancer of activin-like receptor-1 signaling. Faseb J 23: 3712–3721.
43. Lux A, Salway F, Dressman HK, Kroner-Lux G, Hafner M, et al. (2006) ALK1
signalling analysis identifies angiogenesis related genes and reveals disparity
between TGF-beta and constitutively active receptor induced gene expression.
BMC Cardiovasc Disord 6: 13.
44. Fernandez LA, Garrido-Martin EM, Sanz-Rodriguez F, Pericacho M, Rodri-
guez-Barbero A, et al. (2007) Gene expression fingerprinting for human
hereditary hemorrhagic telangiectasia. Hum Mol Genet 16: 1515–1533.
45. Daher Z, Noel J, Claing A (2008) Endothelin-1 promotes migration of
endothelial cells through the activation of ARF6 and the regulation of FAK
activity. Cell Signal 20: 2256–2265.
46. Bhalla A, Haque S, Taylor I, Winslet M, Loizidou M (2009) Endothelin receptor
antagonism and cancer. Eur J Clin Invest 39 Suppl 2: 74–77.
47. Meoli DF, White RJ (2010) Endothelin-1 induces pulmonary but not aortic
smooth muscle cell migration by activating ERK1/2 MAP kinase. Can J Physiol
Pharmacol 88: 830–839.
48. Wang HH, Hsieh HL, Wu CY, Yang CM (2010) Endothelin-1 enhances cell
migration via matrix metalloproteinase-9 up-regulation in brain astrocytes.
J Neurochem 113: 1133–1149.
49. Castanares C, Redondo-Horcajo M, Magan-Marchal N, ten Dijke P, Lamas S,
et al. (2007) Signaling by ALK5 mediates TGF-beta-induced ET-1 expression in
endothelial cells: a role for migration and proliferation. J Cell Sci 120:
1256–1266.
50. Bagnall AJ, Kelland NF, Gulliver-Sloan F, Davenport AP, Gray GA, et al.
(2006) Deletion of endothelial cell endothelin B receptors does not affect blood
pressure or sensitivity to salt. Hypertension 48: 286–293.
51. Nishimura J, Aoki H, Chen X, Shikasho T, Kobayashi S, et al. (1995) Evidence
for the presence of endothelin ETA receptors in endothelial cells in situ on the
aortic side of porcine aortic valve. Br J Pharmacol 115: 1369–1376.
52. Kern JM, Maass V, Rupp J, Maass M (2009) Proliferative stimulation of the
vascular Endothelin-1 axis in vitro and ex vivo by infection with Chlamydia
pneumoniae. Thromb Haemost 102: 743–753.
53. Wendel M, Petzold A, Koslowski R, Kasper M, Augstein A, et al. (2004)
Localization of endothelin receptors in bleomycin-induced pulmonary fibrosis in
the rat. Histochem Cell Biol 122: 507–517.
54. Hall SM, Davie N, Klein N, Haworth SG (2011) Endothelin receptor expression
in IPAH: effect of bosentan and epoprostenol treatment. Eur Respir J 38:
851–860.
55. Wort SJ, Ito M, Chou PC, Mc Master SK, Badiger R, et al. (2009) Synergistic
induction of endothelin-1 by tumor necrosis factor alpha and interferon gamma
is due to enhanced NF-kappaB binding and histone acetylation at specific
kappaB sites. J Biol Chem 284: 24297–24305.
56. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)). Method Methods 25:
402–408.
57. Upton PD, Long L, Trembath RC, Morrell NW (2008) Functional
characterization of bone morphogenetic protein binding sites and Smad1/5
activation in human vascular cells. Mol Pharmacol 73: 539–552.
BMP-9 Induced ET-1 Release in Endothelium Function
PLoS ONE | www.plosone.org 13 January 2012 | Volume 7 | Issue 1 | e30075
